SUMMARY This article reviews recent information concerning the origin of osteoclasts and the local and systemic regulation of their activity. It appears that much of the environmental responsiveness of osteoclasts is mediated by cells of the osteoblastic lineage, which exert a major influence on the localisation, induction, stimulation, and inhibition of osteoclastic bone resorption'. Some of the mechanisms by which osteoclast function may be disturbed by inflammatory and neoplastic diseases are discussed, and it is suggested that many pathological disturbances of osteoclastic bone resorption may be explicable as mimicry of physiological regulatory mechanisms by local hormones introduced into bone as the local regulators of the diseased tissue.
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The osteoclast is the effector of bone resorption. Its activity is normally integrated to the requirements of skeletal morphogenesis and restructuring and to those of calcium homeostasis, but its potential for destruction is shown by the reckless, random resorption which occurs in Paget's disease and in giant cell lesions (in which the multinucleate cells are probably osteoclasts ' 2) . Less conspicuously, but ultimately with similarly devastating effect, the osteoclast is often a party to the development of osteoporosis, to which it contributes with levels of osteolysis above those found in unaffected individuals;3 the scale of this osteoclastic contribution to disease in an ageing population is emphasised by the observation that 30% of all individuals who reach age 90 have sustained a fractured femoral neck and 50% a collapsed vertebra. 4 Osteoclasts act in collaboration with pannus in the osteoarticular destruction of rheumatoid arthritis, and osteoclasts effect tooth loosening and loss in periodontal disease.
In non-metastatic hypercalcaemia, which commonly mars and shortens survival irrespective of the extent of tumour spread, there is release into the circulation by the tumour of stimulators of osteoclastic bone resorption. 56 Despite its central role in these pathological processes, and largely due to its inaccessibility, the osteoclast has been a poorly understood cell. In recent years, however, new information has been gleaned concerning the origin of osteoclasts and the Accepted for publication 4 December 1985 humoral and cellular control of their resorptive activity.
Natural history
Osteoclasts form by fusion of mononuclear precursors. Parabiosis experiments, quail-chick chimaeras, and bone marrow and spleen cell transplantation experiments have established that while osteoblasts derive from local mesenchyme, osteoclasts take origin from a cell which can reach bone via the circulation. 7 8 Among circulating cells the mononuclear phagocyte initially seemed the most plausible precursor, similarly specialised for degradation and capable of fusion.9 Macrophages, however, are unable to correct the osteoclastic defect, curable by bone marrow, in osteopetrosis (Chambers, unpublished observation; JF Loutit, personal communication);'0 they are also incapable of restoring radiation induced reductions in osteoclast number and function." Osteoclasts lack enzymes such as chloroacetate esterase, '2 present quite different from resorption of extracellular bone surfaces. Both mono-and multinucleated macrophages lack the ruffled border characteristic of osteoclasts, '5 16 and are without perceptible effect on bone slices in which osteoclasts, under identical conditions, rapidly induce deep excavations . Osteoclasts lack Fc and C3 receptors, '8 19 and all the macrophage specific antigenic markers so far studied are absent from osteoclasts.' [20] [21] [22] Mature mononuclear phagocytes are thus clearly quite different from osteoclasts. Nevertheless, special environmental conditions might induce the osteoclastic phenotype in immature mononuclear phagocytes. It has been proposed that 1, 25 
Systemic regulation
The bone apposed surface of osteoclasts actively engaged in resorption reveals a distinctive appearance. The central area is elaborately folded (ruffled border) and interdigitates with bone crystals and with frayed collagen fibrils. This is surrounded by a clear zone, rich in actin filaments and free from organelles, of close apposition of osteoclast to the bone, which probably serves as a peripheral seal confining an inner micro-environment into which lysosomal enzymes are extruded. 4'-43 Administration of PTH in vivo is followed within minutes by an increase in the proportion of osteoclasts which show a ruffled border, in the extent of the ruffled border on each cell, and within a few hours, in the overall number of osteoclasts. One mechanism by which osteoblasts stimulate osteoclastic bone resorption appears to be through mineral exposure.7 All bone surfaces, except in areas of osteoclastic resorption, are lined by a layer of unmineralised osteoid.64-66 This is readily visible by light microscopy during bone formation. When formation ceases mineralisation continues for a while but is arrested within a few hundred nanometers of the bone surface, at the level of the lamina limitans; this is a zone of altered staining properties, the specific function of which may be to inhibit progression of the mineralising front to the bone surface. 67 We have found that osteoclasts do not resorb bone if the osteoid layer is intact (nor do they resorb demineralised slices of cortical bone) but do so if the osteoid is first removed by collagenase.ss Since osteoclasts are clearly capable of destruction of all the components of bone56 (Figs. 1-4) , this indicates that contact with bone mineral, but not osteoid, induces osteoclasts to resorptive activity. We also found69 that osteoblasts are able to remove the surface osteoid layer in vitro, to expose (but seem incapable of resorption of) adjacent mineral; that *Footnote Osteoblasts are strictly the cells which synthesise osteoid. During bone formation some cease osteoid production and become interred in bone as osteocytes. When bone formation ceases osteoblasts take up an inactive appearance and become flattened "resting osteoblasts" or "surface osteocytes". The extent to which these processes are reversible, and to which osteoblasts, resting osteoblasts, and osteocytes share properties and potentialities in common, is not known. In vivo, bone resorption is generally seen in areas adjacent to resting osteoblasts and, accordingly, these cells are generally the candidates as osteoclast stimulators. tion to stress and strain and to transmit these sensations as signals to the bone surface, where new bone formation or resorption is possible.
Osteoblasts respond to mechanical forces and electric potentials (known to be generated by mechanical forces acting on bone9' 92 A second potential mediator of local osteoclasis is osteoclast activating factor (OAF), '22 a lymphokine produced by mitogen stimulated lymphocytes (probably T helper cells) in the presence of macrophages, '23 which stimulates bone resorption in organ culture. Similar material is produced in some solid tumours '24 and in myeloma, '25 126 where it may explain the increased osteoclast mediated osteolysis found adjacent to myeloma cells in bone. '25 127 Like prostaglandin E2 it may act as a bone resorption stimulator through a primary action on osteoblasts '28 (but see reference 126) .
In addition to their potential for local osteolysis, some human tumours produce a combination of systemic osteolysis with hypercalcaemia, which is unrelated to the presence of metastases in bone.5 6107 129 Prostaglandin E2 has been invoked as a possible mediator: 30 it stimulates resorption; infusion into laboratory animals causes hypercalcaemia;"9 and it is implicated in some animal models of nonmetastatic hypercalcaemia."9 The experience of most workers, however, is that a response in man to drugs which inhibit prostaglandin synthetase is UUU . 131 132 unusual. '3 3 OAF and related substances may underly the hypercalcaemia which occurs in some haematological malignancies, including T cell lymphomas, in which hypercalcaemia is a common feature. '33 Most cases of non-metastatic hypercalcaemia occur in patients with renal and urothelial tumours and squamous carcinomas of the head, neck, and bronchus. These patients form a group in whom hypercalcaemia is associated with systemic osteolysis and changes in renal physiology similar to, but not identical with, those caused by PTH.5 134 Ectopic PTH synthesis was once thought to be responsible for this syndrome, but the different renal physiology and low-normal circulating PTH concentrations detected by improved PTH assays in these patients is taken as evidence for the presence of a PTH like humoral mediator of unknown identity. The consensus based on currently available evidence is that neither PTH, vitamin D metabolites, nor prostaglandins are involved in non-metastatic humoral hypercalcaemia in other than rare cases. '35 136 Little is known of the mechanisms by which osteolysis occurs in inflammatory lesions such as rheumatoid arthritis and periodontal disease, although several potential mediators have been identified. '37 - '39 Fig. 4 .
